Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Exelixis, Inc. - Common Stock (NQ:EXEL)

38.13 +0.37 (+0.98%)
Streaming Delayed Price Updated: 10:50 AM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Exelixis Inc (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Setup
Exelixis (EXEL) is a strong growth stock with solid fundamentals—17.5% revenue growth, high profitability, and no debt—plus a bullish technical setup, signaling a potential breakout opportunity. 
Via Chartmill
The Analyst Verdict: Exelixis In The Eyes Of 19 Experts
 
Via Benzinga
Exelixis EXEL Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?
Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts. 
Via Benzinga
Peering Into Exelixis's Recent Short Interest
 
Via Benzinga
Peering Into Exelixis's Recent Short Interest
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL): A Strong Value Investment with Undervalued Potential and Solid Fundamentals
EXELIXIS (EXEL) is a top value stock with strong fundamentals—undervalued P/E, zero debt, high profitability, and solid growth. Ideal for value investors seeking quality at a discount. 
Via Chartmill
Assessing Exelixis: Insights From 20 Financial Analysts
 
Via Benzinga
AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events. 
Via Benzinga
Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans
Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts shaped the update. 
Via Benzinga
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Exelixis Q2 Revenue Falls 11 Percent
Via The Motley Fool
Topics Earnings Intellectual Property
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL): A Prime Example of Affordable Growth in Biotech
EXELIXIS (NASDAQ:EXEL) offers strong growth, fair valuation, and financial health, fitting the "Affordable Growth" strategy with high scores in profitability and low bankruptcy risk. 
Via Chartmill
Topics Bankruptcy
Uncovering Potential: Exelixis's Earnings Preview
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Breakout Potential
EXELIXIS INC (EXEL) combines strong growth fundamentals—high profitability, solid financials, and rising revenue—with bullish technical signals, making it a promising breakout candidate for investors. 
Via Chartmill
Earnings Scheduled For July 28, 2025
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors and breakout traders. 
Via Chartmill
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
Via The Motley Fool
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in High-Growth Oncology Stocks
EXELIXIS (NASDAQ:EXEL) shows strong technical and fundamental growth, meeting Minervini’s Trend Template criteria with high earnings momentum and a bullish chart setup. 
Via Chartmill
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note. 
Via The Motley Fool
Topics Intellectual Property
Assessing Exelixis: Insights From 12 Financial Analysts
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors
EXELIXIS INC (NASDAQ:EXEL) shows strong growth, profitability, and financial health, making it a standout for investors following Louis Navellier’s strategy. With high earnings surprises and... 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation
EXELIXIS INC (NASDAQ:EXEL) offers strong growth potential at a reasonable valuation, backed by solid profitability and a debt-free balance sheet. A compelling pick for growth investors. 
Via Chartmill
2 Stocks to Buy With Less Than $50
Via The Motley Fool
Topics Intellectual Property
EXELIXIS INC (NASDAQ:EXEL) - An Undervalued Biotech Stock With Strong Fundamentals
EXELIXIS (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, zero debt, and robust growth prospects, making it a candidate for value investors. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential
EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup. 
Via Chartmill
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
Topics Intellectual Property
EXELIXIS INC (NASDAQ:EXEL) – A High Growth Momentum Stock with Strong Technical Setup
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support... 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.